VY 3 Flashcards

1
Q

Main Learning Outcome for L3 Drug Discovery and Pre-Clinical Research

A

To gain a brief understanding of the drug discovery process and the challenges ahead

A brief introduction to “pre-clinical research”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 3 types of research approaches?

A
  1. Deductive: conclusions reached by reasoning from general laws to a particular case (testing an existing theory)
  2. Inductive: method of reasoning which obtains general laws from particular facts or examples (use the data to develop a theory)
  3. Empirical approach: discovery by chance, or systematic screening
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How to prove a hypothesis?

A

Hypotheses can never be proven, only disproven

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 4 types of hypotheses?

A
  1. Null hypothesis: H0 (no relationship btw x and y)
  2. Correlative hypothesis: H1 (there is a relationship btw x and y)
  3. Alternative hypothesis: 2 possible alternatives (x1, x2)(confirm one alternative), NOT typical hypothesis type
  4. Directional hypothesis: there is a direction of the relationship btw x and y
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the common problems associated with poor studies?

A
  1. failure to include adequate controls
  2. poor experimental design
  3. failure to recognise multiple causes underlying a phenomenon
  4. Conclusion not completely warranted by the data
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How to prevent ‘failure to include adequate controls’?

A

“Controls” are the most impt ingredients in scientific experiments

Use positive and negative controls

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the importance of positive and negative controls?

A
  • Reference (gold standard): independent method to detect all true positives
  • False-negative (concern): result -ve but actually +ve
  • False positive: result +ve but actually -ve

Sensitivity: probability that a signal (Readout) that should actually BE there (=true positive) is PRESENT

Specificity: Probability that a signal that should actually NOT be there (= true negative) is ABSENT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When to use positive and negative controls?

A

Sensitivity: to detect false-negative results (use positive control)

Specificity: to detect a false positive result (use negative control)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why is there poor experimental design in research?

A
  • exclusion of other factors
  • might need to de-challenge and re-challenge
  • pattern (historical)
  • correlation w exposure

there could be causation or correlation

  • not enough sample size
  • no time period to see whether toxicity develops
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What should be done to recognise multiple causes of a phenomenon?

A

these multiple causes are equally valid for explaining the phenomenon.

Thus, need to design more experiments to reject all other possible causes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the challenge in knowing and controlling variables?

A

Limitation in formulating hypothesis in resolving natural and biological phenomenon (in contrast to phenomenon associated with man-made objects)
- difficult to control all known variables

we should say: our data SUGGEST (we should not use the word prove)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Conclusions cannot be drawn due to _______

A

very limited results

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

A landmark piece of scientific work can solely be based on ________ data

A
  • descriptive data (observation-driven)
  • -> can drive to formulate novel hypothesis

does not always need to be hypothesis-driven

  • a study can answer a specific question (discovery-driven) or test a hypothesis (hypothesis-driven)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How is a new chemical entity launched?

A
  1. Screening
  2. Preclinical
  3. Phase I
  4. Phase II
  5. Phase III
  6. Launch of NCE (new chemical entity) (not previously tested in humans; diagnostic agents excluded)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the steps of drug development process?

A
  1. discovery (target id, lead generation, lead optimisation, lab tests)
  2. preclinical (access safety, biological activity, and formulation; animal studies)
  3. IND
  4. Clinical (I, II, III)
    I: determine safety and dosage (healthy volunteers)
    II: evaluate safety and efficacy (pts)
    III: confirm safety and efficacy (more pts)
  5. NDA
  6. Approval (review application and approval)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the point of IND filing?

A

Summary of preclinical development (info required for clinical studies)
- needed for clinical trials

17
Q

What 2 dimensions of R&D Productivity needs to be optimal?

A
  • efficiency: more affordable drugs via less costly R&D

- effectiveness: more value for the pt via innovative drugs w high-qly info

18
Q

What are some potential contributing factors to the rising cost, but declining output of NCEs?

A
  • R&D budget VS % of sales
  • pressures from shareholders
  • merger mania
  • blockbuster mania
  • drug approval policies are inconsistent and errative
  • change in approach to management as marketing executive have no scientific background is the one calling the shots
  • technology?
19
Q

Technologies only beneficial in the _____

A

long run

future advance in genomic and proteomic medicines

20
Q

Drug development effort is hampered by poor knowledge in _________

A
  • understanding of disease at molecular level (poor diagnosis and classification)
  • genetic variations in patient responses (therapeutic toxicity)
21
Q

Despite the challenges in commercial success, what can we do at the moment?

A

boost morale of scientists so they can be proud of their work in serving public good, but not just the company

22
Q

Drugs are discarded during development during development for reasons that are not __________ or ________ in nature

A
  • technical
  • scientific

Income generated from the drug is not worth it

23
Q

What is the approach that R&D is using that is reducing communication, cross-fertilisation, cooperation and teamwork?

A
  • most pharmas separate their R&D divisions organisationally, operationally, operationally, and often geographically
  • the ‘hands-off mentality’ results from the unrealistic presumption that development can be predictably managed
24
Q

What kind of focus should the furture pharma look towards?

A

incremental improvements have historically been among the most important approaches to advances in therapeutic agents

25
Q

Is there a larger role for non-profit institutions for creating novel drugs?

A

Yes, they can be mobilised to enhance its effort in drug discovery as well as development

26
Q

What issue is pre-clinical research addressing?

A

issues concerning “SAFETY” must adhere to GLP in order for the data acceptable for submission to regulatory agencies

27
Q

What is required for NCE Pre-clinical data package?

A
  • develop a pharmacological profile of the drug
  • determine the acute toxicity of the drug in at least 2 species of animals
  • conduct short-term toxicity studies ranging from 2wks-3mths
28
Q

What kind of lab testing/ profiling is done during Pre-clinical research?

A

in vitro and in vivo lab animal testing

drug candidates will also undergo extensive ADME profiling in animals

29
Q

How is preclinical research done for medical devices?

A

GLP testing for safety of device and its components

undergo biocompatibility testing which helps to show whether a component of the device or all components are sustainable in a living model